All In Biotech

Drug Trial Radar · NCT05901831

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Addition to Standard of Care, in Participants With Chronic Kidney Disease and Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 242 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

242

Actual

Start

Feb 26, 2024

Primary completion

Aug 20, 2025

Study completion Sep 15, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes. In people with type 1 diabetes, the body does not make enough of a hormone called insulin, resulting in high blood sugar levels that can cause damage to the kidneys. CKD often occurs together with or as a consequence of type 1 diabetes. The study treatment finerenone works by blocking certain proteins, called mineralocorticoid receptors. An increased stimulation of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease progressively getting worse. Finerenone is approved for doctors to prescribe to people with CKD and type 2 diabetes. In this study, researchers want to learn if finerenone works better than placebo in reducing the participants' kidney disease from getting worse when given in addition to standard of care (SOC) treatment. A placebo looks like a treatment but does not have any medicine in it. SOC is a procedure or treatment that medical experts consider most appropriate for a condition or disease. To find out how well finerenone works, the level of a protein (albumin) in the urine will be measured. Researchers also want to know how safe finerenone is. To do this, the researchers will collect the number of participants with: * medical problems (also called treatment-emergent adverse events (TEAEs)) * serious TEAEs. A TEAE is considered 'serious' when it leads to death, puts the participant's life at risk, requires hospitalization, causes disability, causes a baby being born with medical problems, or is medically important * higher than normal blood levels of potassium (hyperkalaemia). Depending on the treatment group, the participants will either take finerenone or placebo, Importantly, the participants will also continue to take their regular SOC medicines. The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, they will visit the study site at least 6 times. The study team will: * collect blood and urine samples * check the participants' vital signs such as blood pressure and heart rate * do a physical examination including height and weight * check the participants' heart health by using an electrocardiogram (ECG) * do pregnancy tests in women of childbearing potential

Conditions

  • Chronic Kidney Disease
  • Type 1 Diabetes Mellitus

Interventions

  • FinerenoneDrug

    Dose A, Dose B, oral

  • PlaceboOther

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in UACR From Baseline (Ratio to Baseline) Over 6 MonthsTime frame: From baseline to Month 6

Locations

79 sites in 9 countries. Site status is shown where the registry gives one.

  • Southwest Kidney Institute, PLC - Suprise

    Surprise, Arizona

  • Stanford Endocrinology Clinic

    Stanford, California

  • Touro University California - Metabolic Research Center

    Vallejo, California

  • UHealth Diabetes Research Center - Miami

    Miami, Florida

  • AdventHealth Translational Research Institute

    Orlando, Florida

  • CTR Oakwater, LLC

    Orlando, Florida

  • Hanson Clinical Research Center, Inc.

    Port Charlotte, Florida

  • Jedidiah Clinical Research

    Tampa, Florida

  • Metabolic Research Institute, Inc.

    West Palm Beach, Florida

  • Grady Memorial Hospital - Endocrinology

    Atlanta, Georgia

  • Northwestern University | Feinberg School of Medicine - Division of Endocrinology, Metabolism and Molecular Medicine

    Chicago, Illinois

  • UChicago Medicine Kovler Diabetes Center

    Chicago, Illinois

  • Preventive Intervention Center - Endocrinology

    Iowa City, Iowa

  • Wichita Nephrology Group, PA

    Wichita, Kansas

  • Omega Clinical Research - Metairie

    Metairie, Louisiana

  • MedStar Health Research Institute

    Hyattsville, Maryland

  • Joslin Diabetes Center

    Boston, Massachusetts

  • MU Health Care - University Hospital - Endocrinology

    Columbia, Missouri

  • Center for Advanced Medicine - Diabetes Center

    St Louis, Missouri

  • UNC Endocrinology, Diabetes, and Obesity Clinical Research Unit

    Chapel Hill, North Carolina

  • Physicians East, P.A.- W. H. Smith - Endocrinology

    Greenville, North Carolina

  • Accellacare - Wilmington

    Wilmington, North Carolina

  • Cleveland Clinic - Main Campus - Endocrinology

    Cleveland, Ohio

  • OHSU Physicians Pavillion - Endocrinology

    Portland, Oregon

  • UT Health San Antonio - Medical Arts & Research Center - Endocrinology

    San Antonio, Texas

  • Consano Clinical Research, LLC.

    San Antonio, Texas

  • EVMS Strelitz Diabetes Center

    Norfolk, Virginia

  • Providence Medical Research Center

    Spokane Valley, Washington

  • Richmond Road Diagnostic and Treatment Centre | Clinical Trials Unit

    Calgary, Alberta, Canada

  • Alberta Diabetes Institute | Clinical Research Unit (CRU)

    Edmonton, Alberta, Canada

  • Toronto General Hospital - University Health Network, Renal Physiology laboratory

    Toronto, Ontario, Canada

  • Research Institute of the McGill University Health Centre | McConnell Centre for Innovative Medicine

    Montreal, Quebec, Canada

  • Centre hospitalier universitaire de Québec (CHUQ) | Cardiology

    Québec, Quebec, Canada

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Southern Medical University - Nanfang Hospital (Southern Hospital)

    Guangzhou, Guangdong, China

  • Zhongshan People's Hospital

    Zhongshan, Guangdong, China

  • The 4th Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The Central Hospital of Wuhan, Tongji Medl Collg Huazhong...

    Wuhan, Hubei, China

  • Huai'an First People's Hospital, Nanjing Medical University

    Huai'an, Jiangsu, China

  • Nanjing Medical University (NMU) - The Second Affiliated Hospital

    Nanjing, Jiangsu, China

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.